Moby summary of Tilray Brands, Inc.'s Q4 2026 earnings call
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Tilray Brands Inc (TLRY) reports significant financial improvements and outlines strategic plans for future expansion across diverse sectors.
Tilray Brands (NASDAQ:TLRY) reported record fiscal 2026 revenue and adjusted EBITDA, supported by growth in international cannabis, pharmaceutical distribution, wellness and the fourth-quarter acquisition of BrewDog. For the fiscal year ended May 31, 2026, net revenue rose 11% to $915.5 million fro
The president directed federal authorities to reschedule medical marijuana.
SNDL faces pressure after Q1 results show falling sales, weak cannabis demand, and margin strain, raising concerns about growth in a saturated Canadian market.
Tilray Brands (TLRY) surged in premarket trading on fresh enthusiasm over marijuana rescheduling, then gave back much of the move as the session unfolded. The early excitement followed a U.S. government shift to reclassify certain marijuana products and a market rush into cannabis names. By later ...